NasdaqGS:BBIOBiotechs
BridgeBio Pharma (BBIO) Valuation Check After Insider Selling And Upcoming Infigratinib Trial Updates
BridgeBio Pharma (BBIO) is back in the spotlight as investors weigh recent insider selling against upcoming catalysts, including a January 9 webinar on infigratinib and a J.P. Morgan Healthcare Conference presentation.
See our latest analysis for BridgeBio Pharma.
The share price closed at US$73.42 after a 6.15% one day share price decline and a softer 7 day share price return. However, a 32.77% 90 day share price return and very large 3 year total shareholder return suggest longer term...